Literature DB >> 28658834

A Case of a Rapidly Enlarging Neck Mass with Airway Compromise.

Libardo Rueda Prada1, Venkata Sandeep Koripalli1, Cesar Luis Merino1, Ilmana Fulger2.   

Abstract

Anaplastic Thyroid Carcinoma (ATC) is one of the most lethal tumours in humans, extremely rare in occurrence and very aggressive in nature. We hereby present a rare case of ATC with airway compromise. A 66-year-old male, presented complaining of a non-tender anterior neck mass rapidly increasing in size associated with dry cough, hoarseness and voice changes. Imaging studies revealed a large heterogeneous centrally necrotic lobulated left thyroid mass with metastatic lymph nodes and rightward tracheal deviation. Core biopsy and immunohistochemistry stains revealed a profile consistent with ATC. Patient's airway was compromised. Options for treatment and prognosis were discussed. Patient was discharged home with home hospice. A high index of suspicion for ATC is necessary in patients presenting with a rapidly enlarging neck mass. A prompt cytologic evaluation with metastatic work up is important to establish diagnosis. Due to its poor prognosis, an honest discussion regarding end-of-life issues must be initiated at diagnosis. Novel therapies toward genetic and epigenetic pathways have been developed, which is the basis of current clinical trials that are intended to improve clinical outcomes in the coming years.

Entities:  

Keywords:  Anaplastic thyroid carcinoma; Genetic therapy; Palliative care; Patient comfort; Prognosis; Thyroid neoplasms

Year:  2017        PMID: 28658834      PMCID: PMC5483736          DOI: 10.7860/JCDR/2017/25685.9874

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  8 in total

1.  Anaplastic thyroid carcinoma: a 50-year experience at a single institution.

Authors:  B McIver; I D Hay; D F Giuffrida; C E Dvorak; C S Grant; G B Thompson; J A van Heerden; J R Goellner
Journal:  Surgery       Date:  2001-12       Impact factor: 3.982

2.  Real-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid Carcinoma.

Authors:  Vlad C Sandulache; Michelle D Williams; Stephen Y Lai; Charles Lu; William N William; Naifa L Busaidy; Gilbert J Cote; Rajesh R Singh; Rajyalakshmi Luthra; Maria E Cabanillas
Journal:  Thyroid       Date:  2016-11-29       Impact factor: 6.568

3.  Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene.

Authors:  Avaniyapuram Kannan Murugan; Mingzhao Xing
Journal:  Cancer Res       Date:  2011-05-19       Impact factor: 12.701

4.  Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

Authors:  David M Hyman; Igor Puzanov; Vivek Subbiah; Jason E Faris; Ian Chau; Jean-Yves Blay; Jürgen Wolf; Noopur S Raje; Eli L Diamond; Antoine Hollebecque; Radj Gervais; Maria Elena Elez-Fernandez; Antoine Italiano; Ralf-Dieter Hofheinz; Manuel Hidalgo; Emily Chan; Martin Schuler; Susan Frances Lasserre; Martina Makrutzki; Florin Sirzen; Maria Luisa Veronese; Josep Tabernero; José Baselga
Journal:  N Engl J Med       Date:  2015-08-20       Impact factor: 91.245

5.  Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.

Authors:  Julio C Ricarte-Filho; Mabel Ryder; Dhananjay A Chitale; Michael Rivera; Adriana Heguy; Marc Ladanyi; Manickam Janakiraman; David Solit; Jeffrey A Knauf; R Michael Tuttle; Ronald A Ghossein; James A Fagin
Journal:  Cancer Res       Date:  2009-06-01       Impact factor: 12.701

Review 6.  Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches.

Authors:  Chandrakanth Are; Ashok R Shaha
Journal:  Ann Surg Oncol       Date:  2006-02-15       Impact factor: 5.344

7.  American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer.

Authors:  Robert C Smallridge; Kenneth B Ain; Sylvia L Asa; Keith C Bible; James D Brierley; Kenneth D Burman; Electron Kebebew; Nancy Y Lee; Yuri E Nikiforov; M Sara Rosenthal; Manisha H Shah; Ashok R Shaha; R Michael Tuttle
Journal:  Thyroid       Date:  2012-11       Impact factor: 6.568

8.  Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery.

Authors:  J Tennvall; G Lundell; P Wahlberg; A Bergenfelz; L Grimelius; M Akerman; A-L Hjelm Skog; G Wallin
Journal:  Br J Cancer       Date:  2002-06-17       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.